This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Euthymics Bioscience, Inc.
Drug Names(s): DOV 216,303
Description: DOV 216,303 is a triple-reuptake inhibitor. It inhibits the reuptake of the catecholamines serotonin, norepinephrine, and dopamine.
Deal Structure: On August 5, 2004, DOV entered into an agreement with Merck for the worldwide development and commercialization of DOV 21,947 for all therapeutic indications and of DOV 216,303. Merck assumed financial responsibility for development and commercialization of a product containing at least one of the licensed compounds. The parties agreed to work together to clinically develop licensed product and DOV has reserved the right to co-promote the sales of product in the U.S.
Under the agreement, DOV received a $35.0 million up-front licensing payment. In addition, DOV could receive as much as $300.0 million for achieving certain clinical development and regulatory milestones for multiple territories and approval of two indications, and up to $120.0 million upon achievement of certain sales thresholds.
In August 2005, DOV announced that its license agreement with Merck for DOV 21,947 and DOV 216,303 had been amended. The milestones, royalties and business terms originally established in...See full deal structure in Biomedtracker
DOV 216,303 News
Additional information available to subscribers only: